Abstract
Mutated BRAF serine/threonine kinase is implicated in several types of cancer, with particularly high frequency in melanoma and colorectal carcinoma. We recently reported on the development of BRAF inhibitors based on a tripartite A-B-C system featuring an imidazo[4,5]pyridin-2-one group hinge binder. Here we present the design, synthesis, and optimization of a new series of inhibitors with a different A-B-C system that has been modified by the introduction of a range of novel hinge binders (A ring). The optimization of the hinge binding moiety has enabled the development of compounds with low nanomolar potencies in both BRAF inhibition and cellular assays. These compounds display optimal pharmacokinetic properties that warrant further in vivo investigations.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology
-
Benzenesulfonates / chemistry
-
Biological Availability
-
Crystallography, X-Ray
-
Female
-
Humans
-
Hydrogen Bonding
-
Imidazoles / chemistry
-
Mice
-
Mice, Inbred BALB C
-
Models, Molecular
-
Neoplasm Transplantation
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Protein Binding
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Proto-Oncogene Proteins B-raf / chemistry
-
Pyrazines / chemical synthesis*
-
Pyrazines / pharmacokinetics
-
Pyrazines / pharmacology
-
Pyridines / chemical synthesis*
-
Pyridines / chemistry
-
Pyridines / pharmacokinetics
-
Pyridines / pharmacology
-
Sorafenib
-
Structure-Activity Relationship
-
Transplantation, Heterologous
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
Imidazoles
-
Phenylurea Compounds
-
Pyrazines
-
Pyridines
-
Niacinamide
-
Sorafenib
-
Proto-Oncogene Proteins B-raf